Navigation Links
Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Date:5/1/2008

-- Presentations highlight Palomid 529 as an inhibitor of macular

degeneration, diabetic retinopathy and retinal scaring from retinal

detachment in animal disease models ---

JAMAICA PLAIN, Mass., May 1 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. today announced it has presented two presentations at the 2008 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) describing the activity of Palomid 529 in a series of models of retinal disease notably macular degeneration, diabetic retinopathy and retinal fibrosis.

P529 is a non-steroidal, synthetic, small molecule drug created through computational design, synthetic and medicinal chemistry, the result of three generations of Palomid design work. Palomid's broad activity as an anti-angiogenic and anti-proliferative agent is shown to reside in its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway as a TORC1/TORC2 inhibitor.

The first of the two presentations, "Palomid 529, a Non-Steroidal Small Molecule Anti-Angiogenic Agent Inhibits Retinal and Subretinal Neovascularization by Inhibiting the PI3K/Akt/mTOR Pathway", was given as an oral presentation by Dr. David Sherris, President and CEO of Paloma Pharmaceuticals. The second presentation, "Muller Cell Proliferation and Glial Scar Formation Is Reduced Following Experimental Retinal Detachment Using Palomid 529, an Inhibitor of the Akt/mTOR Pathway", was given by the Drs. Geoffrey P. Lewis and Steven. K. Fisher, presented by Dr. Ethan A. Chapin, of the Neuroscience Research Institute, Neuroscience Research Institute, MCD Biology, University of California-Santa Barbara, Santa Barbara, CA.

"Ocular diseases of both retinal and sub-retinal origin, namely diabetic retinopathy and age-related macular degeneration, are a significant problem in our aging population. In order to create a drug to optimally treat such diseases one needs to prevent or inhibit disease pr
'/>"/>

SOURCE Paloma Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Palomar to Unveil New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery
2. Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology
3. Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting
4. Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms
5. Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
7. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
8. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
9. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
10. Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings
11. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... -- Drugs commonly used to treat glaucoma may cause ... with vision, according to a new study. The ... to reduce eye pressure, have already been shown to ... the researchers said, suggesting that the new findings could ... should be conservative when prescribing these drugs, the researchers ...
(Date:5/24/2013)... Lake City, Utah (PRWEB) May 24, 2013 ... 2.0 , with exciting new enhancements for instructors and ... students stay more focused through personalize learning plan templates, ... new AnatomyOne release provides 500 new assessment questions, 5,000 ... and review notes. , AnatomyOne 2.0 is ...
(Date:5/24/2013)... BestSatelliteProviders.com the online satellite TV and ... compare the features and services offered by leading ... the rankings of the best rural Internet ... on their website. , BestSatelliteProviders.com – ... Matthews, the spokesperson for BestSatelliteProviders.com, “When consumers were ...
(Date:5/24/2013)... to the National Institutes of Health, Stevens Johnson Syndrome (SJS) ... the skin and mucous membranes. SJS occurs most commonly ... (i). In the early stages SJS presents flu-like symptoms, ... it affects the mucous membranes such as the eyes, mouth ... eye causes conjunctivitis (pink eye). Inflammation of the mouth ...
(Date:5/24/2013)... News) -- The number of U.S. patients admitted ... in an emergency room has increased by nearly ... study, conducted by researchers at the George Washington ... in Washington, D.C., found that patients wait five ... being admitted to the ICU. The researchers said ...
Breaking Medicine News(10 mins):Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2
... The Diversified Agency Services (DAS),unit of Omnicom ... position of,Executive Vice President and Director of ... will direct the client-centric and,brand-centric teams within ... resource of specialist agencies that support,the strategic ...
... is ,good news, for postmenopausal women taking anastrozole ... to previous study results, the cancer prevention drug ... cognitive performance, a new study found. , ... tamoxifen in preventing breast cancer recurrence in postmenopausal ...
... WINSTON-SALEM, N.C. Scientists at Wake Forest University School ... cancer gene called HNF1B have found a second independent ... increasing the number of genetic variants that may ... comparing the newly-discovered site with a previously discovered site ...
... , The guidelines are developed through a rigorous ... the field and a review committee of 21 international ... the first time both acute and chronic heart failure. ... patients with acute heart failure often develop chronic problems ...
... largest multi-institutional study to date examining the impact of ... individuals with suspected recurrent colorectal cancer, researchers found that ... patients, according to an article in the September issue ... The study was conducted at four sites throughout Australia ...
... Dr. Charmaine Yoest,President and CEO of Americans United ... that the daughter of McCain running mate,Sarah Palin is ... know this situation is not the ideal,Sarah Palin wished ... life,s,challenges is the true testament to our character. The ...
Cached Medicine News:Health News:Sharon Callahan Joins Diversified Agency Services Unit of Omnicom Group 2Health News:Breast Cancer Drug Not Tied to Cognitive Decline: Study 2Health News:Scientists find second site for prostate cancer gene 2Health News:PET scans lead to treatment changes in majority of colorectal cancer patients 2
(Date:5/23/2013)... BRAINTREE, Mass. , May 23, 2013  Haemonetics Corporation ... Chris Lindop , CFO & EVP-Business Development, will present ... Care Conference in Boston, MA on ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may ... About Haemonetics Haemonetics (NYSE: ...
(Date:5/23/2013)... Minn. , May 23, 2013  MGC Diagnostics ... a global medical technology company, today scheduled a conference ... quarter of fiscal year 2013, ended April 30, 2013. ... Thursday, May 30, 2013. The Company will report financial ... after the markets close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly ... property developed and owned by Hadassah University Hospital, ... center, today announced that its portfolio company, Cell ... Israeli Ministry of Industry and Commerce, Office of ... and advance clinical trials. Cell Cure,s development budget ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... The SCOOTER Store today announced a major milestone, saying it has ... power wheelchair to Earvin Thompson of Houston, Texas . ... leading provider of power mobility equipment, will enjoy more freedom and independence ... , ...
... GRONINGEN, The Netherlands , June 22, 2010 ... announced this week that in collaboration,with the University ... for the treatment of inhalation anthrax. In a rabbit ... time to treatment (48h post,infection) with a combination of ...
Cached Medicine Technology:The SCOOTER Store Marks Half-Millionth Life Changed 2The SCOOTER Store Marks Half-Millionth Life Changed 3The SCOOTER Store Marks Half-Millionth Life Changed 4Survival Rate Up to 100% for Late Stage Treatment of Anthrax Infections 2
This ENDOLOOP suture has a suture type - 0 PDSII and a 1.5 inch diameter....
This ENDOLOOP suture has a suture type - 0 Coated VICRYL and a 1.5 inch diameter....
... bring modern Data Management capabilities to the ... wide range of settings and definable options, ... the operator for identification, lot numbers, quality ... This data can then be transmitted to ...
Bartels Clostridium difficile Toxin A Enzyme Immunoassay (EIA) is intended for the qualitative detection of Clostridium difficile Toxin A in human faecal specimens as an aid in the diagnosis of Clost...
Medicine Products: